Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fasting test may unlock personalized obesity treatment

NCT ID NCT06874270

Knowledge-focused Sponsor: University Hospital Schleswig-Holstein Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study explores whether a 24-hour fast can identify two metabolic types in people with severe obesity: 'thrifty' (whose metabolism slows significantly) and 'spendthrift' (whose metabolism stays steady). Researchers will track weight loss during a 12-week very-low-calorie diet and a 12-week maintenance phase to see if the thrifty type loses less weight. The goal is to develop a simple test that personalizes obesity therapy based on an individual's unique metabolism.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple test that helps doctors choose the most effective weight loss plan for each person with severe obesity.
What could go wrong
This is a small, early-stage study with only 35 participants. The metabolic types identified may not reliably predict weight loss success in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

35 people

The number who actually took part.

Started

Sep 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult men and women (ages 18 to 70) with a body mass index (BMI) above 40 kg/m² who are receiving care at the Department of Internal Medicine I at the University Hospital Schleswig-Holstein (UKSH), Campus Kiel. All participants are enrolled in a multimodal obesity therapy program that includes nutritional counseling, behavioral interventions, and exercise components. Eligible individuals must meet the specified inclusion criteria and have no conditions that could confound study results or compromise patient safety.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Morbid obesity (BMI \> 40 kg/m²) * Currently undergoing a multimodal obesity therapy program at the Department of Internal Medicine I at the University Hospital Schleswig-Holstein (UKSH), Campus Kiel Exclusion Criteria: * Type 1 or Type 2 diabetes mellitus, or fasting blood glucose \>125 mg/dL, or HbA1c \>6.5% * Conditions affecting appetite or energy expenditure (e.g., Cushing's syndrome, uncontrolled hyper-/hypothyroidism, diabetes mellitus) * Gastrointestinal diseases that may impair nutrient absorption (e.g., inflammatory bowel disease, malabsorption syndromes, peptic ulcers) * Psychiatric disorders that influence eating behavior (e.g., active depression, anorexia nervosa, bulimia nervosa, borderline personality disorder) * Acute, unstable cardiovascular disease requiring hospitalization within the last 6 months (e.g., stent implantation) * Cancer requiring treatment within the past 5 years * Chronic kidney disease at Stage IV or worse according to NKF criteria * Active infectious disease (e.g., HIV, hepatitis) * Active nicotine use * Drug use (e.g., amphetamines, cocaine, heroin, marijuana) * Regular intense physical activity (≥1 hour of sport per day) * Non-MRI-compatible metallic implants (e.g., joint replacements, metal plates) * Pregnancy or breastfeeding * Use of weight-loss medications * Clinically relevant claustrophobia * Any other condition not specified above that, in the judgment of the investigator, could interfere with study participation or compromise patient safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Morbid obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fasting morbid obesity Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity and overweight

Contacts and locations

Locations

  • University Hospital Schleswig-Holstein

    Kiel, Schleswig-Holstein, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.